| Literature DB >> 33667686 |
José C J M D S Menezes1, Marc F Diederich2.
Abstract
Natural biflavonoids, such as amentoflavone, bilobetin, ginkgetin, isoginkgetin, taiwaniaflavone, morelloflavone, delicaflavone, hinokiflavone, and other derivatives (~ 40 biflavonoids), are isolated from Selaginella sp., Ginkgo biloba, Garcinia sp., and several other species of plants. They are able to exert therapeutic benefits by regulating several proteins/enzymes (PPAR-γ, CCAAT/enhancer-binding protein α [C/EBPα], STAT5, pancreatic lipase, PTP1B, fatty acid synthase, α-glucosidase [AG]) and insulin signaling pathways (via PI3K-AKT), which are linked to metabolism, cell growth, and cell survival mechanisms. Deregulated insulin signaling can cause complications of obesity and diabetes, which can lead to cognitive disorders such as Alzheimer's, Parkinson's, and dementia; therefore, the therapeutic benefits of these biflavones in these areas are highlighted. Since biflavonoids have shown potential to regulate metabolism, growth- and survival-related protein/enzymes, their relation to tumor growth and metastasis of cancer associated with angiogenesis are highlighted. The translational role of biflavones in cancer with respect to the inhibition of metabolism-related processes/pathways, enzymes, or proteins, such as STAT3/SHP-1/PTEN, kinesins, tissue kallikreins, aromatase, estrogen, protein modifiers, antioxidant, autophagy, and apoptosis induction mechanisms, are discussed. Finally, considering their observed bioactivity potential, oral bioavailability studies of biflavones and related clinical trials are outlined.Entities:
Keywords: 2,3-Dihydroamentoflavone (Pubchem CID-44420106); 2′,8″-Biapigenin (Pubchem CID-11958336); 3,8″-Biapigenin (Pubchem CID-10414856); 6,6″-Biapigenin (Pubchem CID-23757236); 7,7″-Dimethoxyagastisflavone (Pubchem CID-9985405); Agathisflavone (Pubchem CID-5281599); Alzheimer’s; Amentoflavone (Pubchem CID-5281600); Angiogenesis; Anticancer; Apoptosis induction; Biacacetin (Pubchem CID-122179776); Biflavonoids; Bilobetin (Pubchem CID-5315459); Bioavailability; Chamaejasmenin B (Pubchem CID-21676273); Diabetic agent; Dihydromorelloflavone (Pubchem CID-11467081); Fatty acid synthase; Fukugeside (Pubchem CID-101560895); Ginkgetin (Pubchem CID-5271805); Glucosidase inhibition; Hinokiflavone (Pubchem CID-5281627); Isochamaejasmenin B (Pubchem CID-11753405); Isoginkgetin (Pubchem CID-5318569); Metastasis; Morelloflavone (Pubchem CID-5464454); Obesity therapy; Ochnaflavone (Pubchem CID-5492110); PPAR-γ expression; PTP1B inhibitors; Pancreatic lipase; Sciadopitysin (Pubchem CID-5281696); Taiwaniaflavone (Pubchem CID-44456685); Volkensiflavone (Pubchem CID-5480834)
Mesh:
Substances:
Year: 2021 PMID: 33667686 DOI: 10.1016/j.phrs.2021.105525
Source DB: PubMed Journal: Pharmacol Res ISSN: 1043-6618 Impact factor: 7.658